Zobrazeno 1 - 10
of 20
pro vyhledávání: '"John D. Zubkus"'
Autor:
John D. Hainsworth, John D. Zubkus, Mythili Shastry, Patrick J. Ward, L Finney, Denise A. Yardley, Aruna Mani, Dianna Shipley, Gail Lynn Shaw Wright, Laura M. DeBusk
Publikováno v:
Clinical Breast Cancer. 19:1-9
Background Eribulin mesylate is a non–taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epith
Autor:
Howard A. Burris, F. Anthony Greco, Davey B. Daniel, John D. Hainsworth, David R. Spigel, Tarek Mekhail, John D. Zubkus, Dianna Shipley, David M. Waterhouse
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 117
Purpose First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. Amrubicin is a synthetic anthracycline with single-agent activity in relapsed/refractory SCL
Autor:
Janice F. Eakle, L Finney, John D. Hainsworth, Denise A. Yardley, Brooke R. Daniel, John D. Zubkus, Davey B. Daniel, Rebecca Bechhold
Publikováno v:
Clinical Breast Cancer. 15:251-258
Background Ixabepilone is a member of the epothilone class of antineoplastic agents with activity against taxane-resistant tumors, and low susceptibility to common mechanisms of tumor resistance. This study evaluated ixabepilone in lieu of a taxane i
Autor:
Jeffrey R. Infante, Lowell L. Hart, F. Anthony Greco, David R. Spigel, Victor G. Gian, Charles D. Webb, Martin J. Bury, David M. Waterhouse, Dianna Shipley, Howard A. Burris, John D. Hainsworth, John D. Zubkus
Publikováno v:
Lung Cancer. 78:70-75
Background Epothilones, a new class of cytotoxic agents, have demonstrated activity in non-small-cell lung cancer (NSCLC). This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-lin
Autor:
Thorvardur R. Halfdanarson, Benjamin Rolland Nadeau, Wei Li, Laura Borodyansky, James D. Peyton, John D. Zubkus, J. Edenfield, Youzhi Li, Henry C. Pitot, C. J. Li, Derek J. Jonker, Joleen M. Hubbard, Johanna C. Bendell, Axel Grothey, B. O’Neil, Alexander Starodub, Bamidele Adesunloye
Publikováno v:
Annals of Oncology. 28:iii150-iii151
Autor:
Denise A. Yardley, Brooke R. Daniel, Yuval Naot, Elizabeth R. Vazquez, Howard A. Burris, Roger Inhorn, John D. Zubkus, John D. Hainsworth, Cassie M. Lane
Publikováno v:
Clinical Breast Cancer. 10:367-372
Background Neoadjuvant anthracycline/taxane combinations, with or without gemcitabine, produce pathologic complete responses (pCRs) in 15%-25% of patients. In this multicenter phase II study, we attempted to increase efficacy and decrease toxicity of
Autor:
Alexander Starodub, Thorvardur R. Halfdanarson, Benjamin Rolland Nadeau, Bert H. O'Neil, Derek J. Jonker, William Jeffery Edenfield, Johanna C. Bendell, Youzhi Li, Joleen M. Hubbard, Laura Borodyansky, Bamidele Adesunloye, Chiang Li, Wei Li, Henry C. Pitot, John D. Zubkus, Axel Grothey, James D. Peyton
Publikováno v:
Journal of Clinical Oncology. 35:3529-3529
3529 Background: Cancer stem cells are considered to be fundamentally important for resistance, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor in development identified by its ability to inhibit STAT3-driven gene
Autor:
Kent C. Shih, Mark Mainwaring, Michael Brian Hemphill, Jaswinder Singh, Johanna C. Bendell, Dianna Shipley, James D. Peyton, L. Johnetta Blakely, John D. Zubkus, David Wright, Andrew S. Kennedy
Publikováno v:
Journal of Clinical Oncology. 35:e15040-e15040
e15040 Background: SIRT (or radioembolization) has been successfully used in the tx of mCRC patients with liver mets who are not surgical candidates. The addition of the multi-kinase inhibitor, regorafenib to SIRT is an attractive option as anti-tumo
Autor:
Douglas B. Flora, Donald Gravenor, F. A. Greco, John D. Hainsworth, Howard A. Burris, Davey B. Daniel, John D. Zubkus, David R. Spigel, Tarek Mekhail, David Michael Waterhouse, Dianna Shipley
Publikováno v:
Journal of Clinical Oncology. 30:7100-7100
7100 Background: Amrubicin is a novel anthracycline associated with high objective response rates (ORR) in patients (pts) with relapsed SCLC. Amrubicin improved the ORR and progression-free survival (PFS) in relapsed SCLC vs. topotecan, but not overa
Autor:
Janice F. Eakle, John D. Zubkus, H. A. Burris, Mythili Shastry, D. A. Yardley, P. S. Tucker, Rebecca Bechhold, Davey B. Daniel, John D. Hainsworth
Publikováno v:
Journal of Clinical Oncology. 29:621-621
621 Background: The combination of docetaxel, carboplatin, and trastuzumab (TCH) is a standard adjuvant and neoadjuvant regimen for patients (pts) with HER2-positive breast cancer. Ixabepilone is a microtubule stabilizer active in taxane-refractory m